Apixaban is a direct oral factor Xa inhibitor anticoagulant used for stroke prevention in non-valvular atrial fibrillation and for treating venous thromboembolism, distinguished by predictable pharmacokinetics that avoid the need for routine coagulation monitoring. Simson Pharma's Apixaban reference standard and impurities support generic development in this fast-growing DOAC category.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Apixaban Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.